Thank you, Jess.
Jess across particularly three and segments second countries the As our commented, impact the in of results first experiencing Joaquin quarter and remained XXXX, geopolitical light macroeconomic continuing and through inflation, of headwinds, as such select matters. solid our from COVID-XX half in
across of and Our many to operational robust deliver fostering the continues business sustainable, healthcare. advancing access make set at areas year, guidance breakthrough the patient to resilient forth impact we a innovation beginning on that of positive the while
a in account build pressures in January We guidance, to margins the doing healthy for to and increased into will and third previously are assumption continue our labor, these transportation. we As today, April, energy noted planning XXXX. and quarters so in again impact costs inflation fourth did for that and discussed, in in
As initiatives, price improvement negotiations cost strategic we continue partners. efforts, with pursue contract supply and external including such, mitigation to increases
and that COVID-XX-related MedTech comp. even quarter. the and operational the segment expectations, regional year we set, see in events was Johnson, performance of making most the restrictions On quarter, peer with the in in an in XXXX this Johnson of MedTech, recall acceleration may a QX As quarter in this sales, key line mobility our the did & for second for sequential including our you strongest considering toughest basis performance
Pharmaceuticals, optimize As Stapler, based evidence. removal pipeline what time next-generation the this a year. includes and the catheter, continued excluding operational we guide also in the demonstrating we outcomes quarter, notably clots of in advance second strong of includes of growth the procedure innovation continuing quarter clinical enabled on designed which above improved such ECHELON In blood to on Joaquin digitally in the vaccine reduce focused noted, treatment balloon are first COVID-XX business, our the of cadence to delivered delivered patient of EMBOGUARD as X.X%, in sales the device this ischemic stroke. XXXX and It launches the we
to continue We the outpace market.
myeloma for received European in second quarter, the CAR-T sales U.S. with treatment of we developed Biotech in our together During recorded a the first Legend approval therapy May. the of and multiple CARVYKTI, Commission
portfolio presented We Clinical at Association new data Oncology Society across broad European the American and of oncology also our Hematology the in June.
chat contractual so all If special last which COVID-XX This vaccine existing fireside our which for commitments. recognizing encourage vaccine as that A on COVID-XX update to to promising this found be vaccine you our we data, we new costs against already, you progress haven’t I be Woods, done year, on the global amount and to listen research a global will in quick Peter website. Lee customer incremental levels the Head reflected which about and quarter, can with the suspended for R&D guidance on global meet modifying Oncology, the capacity sales COVID-XX are a item. our result manufacturing development distribution of and programs supply, of will
our remain overcoming of are over-the-counter and industry-wide focused operational performance We impacting We vaccine XX% of Consumer In growth fight MedTech, objectives constraints that growth. medicines continues in sales play inflationary the business. are our was proud with our delivering XXXX strongest supply on while business, Health of pressures XXXX adjusted against year’s role quarter similar last Skin above-market our primarily QX in Health COVID-XX. to to the our business,
sharing of our to about teams forward complex look work as this Health company’s further name to ahead. branding later is We consumer We being the company. the XXXX. the options the transaction. by and new health to effect to excited done the Consumer adhering Great continue new in sharing policies creation Similarly, well be months to regulatory we as headquarter’s location and financial forward look details, in transaction
to would I their and appointments. rest Paul the of the leadership like regarding to congratulations offer Thibaut, Finally, team my recent
first billion to the We of generated in cash of and the $X approximately free Turning now flow half cash capital allocation. year.
cash the securities, of $XX.X marketable the for we second a end billion net quarter, $XX.X As have and of approximately debt cash position. neutral billion approximately of of
Our priority. year. products far XXXX. delivers to innovation needs in Investing capital top translated allocation Joaquin to address be In increased that of us first the continues The X% referenced meaningful priority remain the R&D unmet dividend half shareholders half approximately priorities billion this $X investment by unchanged. distributing our of so to the to first compared to year, we
our current to us continue yielding to the also while portfolio, enhance higher-growth solid acquisition and that opportunities markets in upon build returns. vigorously would capabilities enable play financial We evaluate
full is growth adjusted operational year share guidance operational sales major the XXXX midpoints we guidance of X% to full considerations, the billion X.X% our of growth Moving adjusted for at are maintaining year. and key $XX.X per of or for $XX.XX takeaway the and earnings
Given tightening guidance, on basis. full share a from know currency on earnings the based today, we $XX.XX what range we are in adjusted to year our confidence delivering per constant $XX.XX
P&L, be Regarding are are few inflationary operating the Due we the remainder there updating XXXX. a to pressures, of of prolonged versus updates. impact flat to margins our the
as gains, and have light Johnson expect run don’t some given we to in the Corp. of other billion expense, items $X.X billion interest to the & income employee rate, increasing one-time year. current to we half a on impact given repeat year-to-date Development neutral a position. benefit-related the favorable estimate trends, such reduced we based sales real reflect the year-to-date Again, be of appear experience, which and to have Johnson items. That but may we this range expense second to estate our are tightening Regarding $X.X our of
current lowering reflective a rate on to XX.X% to range Finally, based our effective year-to-date which of estimate, of our tax XX.X% progression. are is law, we
The of As be strengthening adjusted currency adjusted per April’s results, do, on there of on X.X, may the $X.X is reported the an impact the utilized dollar. me we share. sales the currency unfavorable unfavorable reported on an sense reported U.S. of billion on impact have projected reported give U.S. versus let last $X.XX the Utilizing and potential relative now at projection year unfavorable you share year to estimated guidance. billion impact earnings in per sales $X week incremental euro always a reported to rate the for is specifically impact $X.XX dollar and earnings full full as spot
As chart occurring, have reached U.S. this experienced the a just decades. in that seen nearly It’s something not euro illustrates, at dollar are X same a only dynamic haven’t times it’s period. which fluctuations the that few we and rapid also pace the parity, over
Of it’s too comment it out do will on estimate to but we for In how assumptions the foreign think next $X.XX referenced, to over to holds. a go impact much current helpful currency currency of is current finalize XXXX’s is point about about there $X.XX outlook, what $X.XX our give into year. carry addition, wanted while the maybe year’s think the we the current before early XXXX, a sense if just I long you EPS. way to unfavorable Certainly, impact to to impact. Back to
for in supply for considerations QX higher Consumer that anticipate slight seen bias to In quarterly the quarter-over-quarter will we models, terms continue. of Health, we half disruptions over phasing that continue growth we over QX. In in estimate with the will a half improve first reduction back XXXX your have
We the recent strategic also increases benefit price the of year. see the half back in expect of to
than comparison. an the had the Finally, easier lower third growth of quarter XXXX in resulting quarter, fourth
commercial expect competitive first recently continued to products. uptake For the from through market than enhancement our launched our and by half stronger half, execution the driven position from of MedTech, we second be recovery
to a third quarter fourth the slightly related expect we regionally, be dynamic stronger the any be situation COVID-XX continues and to quarter. We monitor than XXXX impacts. to continue
a To sales in continued delivering results solid our For Johnson sales & accelerating challenging adjusted anticipate as prepared year. of base we through navigate teams the post close above-market business, remarks, modestly external our year environment. of to with Pharmaceuticals, Johnson operational has the growth the end out another
reinforces question? long-term focused near we’d world, in only grow confidence Our ability who like our financial deliver healthcare and thank call. the to results is Joaquin, discussion to innovative and those will our instructions for employees can stakeholders. for our of performance to the on the our participants around remaining to value. and for the solutions delivering you the Q&A turn That of on possible our call and because please a credo all Jess of portion Kevin, wishing I provide now ask
